Skip to main content
SpringerLink
Log in

Dosisdichte neodadjuvante Chemotherapie beim Harnblasenkarzinom

Potenzial für die Zukunft?

Dose density of neoadjuvant chemotherapy for bladder cancer

Potential for the future?

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Plimack ER, Dunbrack RL, Brennan TA et al (2015) Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 68(6):959–967

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Plimack ER, Hoffman-Censits JH, Kutikov A et al (2014) Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): final results of a multicenter phase II study. ASCO Meet Abstr 32(15 suppl):4513

    Google Scholar 

  3. Seiler R, Ashab HA, Erho N et al (2017) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 72(4):544–554

    Article  CAS  PubMed  Google Scholar 

  4. Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 15;19(10):2638–2646 (May)

    Article  Google Scholar 

  5. Tully MC, Bochner BH, Dalbagni G et al (2014) Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND. J Clin Oncol 32(4 suppl):355

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum für Onkologie, II. Medizinische Klinik und Poliklinik (Onkologie, Hämatologie und Knochenmarktransplantation mit Abteilung Pneumologie), Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland

    A. Coym

Authors
  1. A. Coym
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Coym.

Ethics declarations

Interessenkonflikt

A. Coym gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coym, A. Dosisdichte neodadjuvante Chemotherapie beim Harnblasenkarzinom. Onkologe 24, 827–830 (2018). https://doi.org/10.1007/s00761-018-0437-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-018-0437-5

Search

Navigation